Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript
August 8, 2025
Earnings Call Speaker Segments
Thank you, operator, and hello to everyone joining us. We're glad you could be part of today's Heron Therapeutics earnings call, during which we'll review the company's financial results for the quarter ended June 30, 2025. Here with me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Werner, Senior Vice President of Medical Affairs, Strategy and Engagement. For those listening by phone, the slides can be viewed through the webcast, and after today's call concludes, they will also be accessible on the Investor Relations section of our website. Before we begin, I want to take a moment to note that during this call, forward-looking statements will be made by the company. Keep in mind that anything that isn't a historical fact qualifies as such a statement. This includes anything we say about projections, expectations, plans, beliefs, and how the company will perform going forward — all of which fall under the forward-looking category as defined by the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Statements like these are based on judgment and analysis only as of today's call date, and they carry a number of significant risks and uncertainties that might lead actual results to diverge materially from what those statements describe. Details about the dangers and unknowns connected to the predictive remarks shared during this call and webcast can be found in the safe harbor language included in today's press release, as well as in Heron's routine periodic submissions to the SEC. Unless the law demands otherwise, Heron takes on no duty to revise these forward-looking statements so they mirror later occurrences or real results, and it has no plan to do so. Having said that, I'll hand things over now to Craig Collard, Heron's Chief Executive Officer.
Thank you, Melissa. Greetings, everyone, and thanks for joining us on Heron Therapeutics’ Second Quarter 2025 Earnings Call. We're excited today to present our results and the progress achieved during the second quarter and first half of 2025. This has been an extraordinarily busy and transformative stretch for the Heron team, and I'd like to start by acknowledging the enormous hard work and commitment our people have shown. A standout milestone during this quarter was the successful closing of our new financing. It was a complicated and essential endeavor, and I'm pleased to report that our team carried it out with the same precision and focus as always. This financing bolsters our balance sheet, boosts our financial flexibility, and puts us in position to speed up our strategic initiatives with confidence. This accomplishment speaks not only to our dedication to operational excellence, but also to the firm confidence our partners and investors hold in Heron's long-term vision. Now that this new capital is secured, we're better positioned to fuel innovation, grow our commercial efforts, and keep delivering value to patients and shareholders alike. In addition to the successful financing, the Heron team posted robust operational and financial results in the second quarter. We brought in total net revenues of $37.2 million for the quarter and $76.1 million for the first half of 2025. This translated into adjusted EBITDA of $7.9 million for the first half of the year, which shows our ongoing commitment to disciplined execution and operational efficiency. Notably, we're observing steady demand growth for our products ZYNRELEF and APONVIE, which has exceeded net revenue growth across the past 2 quarters. That's an important signal of the fundamental strength of our business and the rising adoption of our products. Mark will go into greater detail on this trend later in our prepared remarks. One more key milestone this quarter involved ZYNRELEF moving from a C-code to a permanent J-code, which takes effect October 1. This represents a major victory for Heron and for the providers who depend on ZYNRELEF in their practice. The J-code will simplify reimbursement procedures and lessen administrative load, particularly as the NOPAIN act keeps building momentum; we expect this shift to enhance access and coverage among both government and commercial payers, ultimately driving wider adoption and improved patient outcomes. All together, these accomplishments highlight the momentum we're generating throughout the organization; we're carrying out our strategy, reinforcing our financial base, and setting Heron up for long-term growth. At this point I'd like to hand the call over to Mark Hensley, our Chief Operating Officer, to discuss product performance and many of the new initiatives we believe will serve as catalysts for future growth. Go ahead, Mark.
Thanks, Craig. For Heron, the second quarter served as a period of transition, during which we put into place a number of important commercial adjustments intended to bolster execution across the back half of the year and going forward. Net revenues combined from APONVIE and ZYNRELEF came to $10.7 million in Q2 and $20.9 million on a year-to-date basis. That represents robust growth versus the prior year of 55.5% for the quarter and 70.5% for the first half of '25 when compared with the equivalent periods in 2024. Within the Acute Care franchise, demand expansion was encouraging, with unit growth seen across both ZYNRELEF and APONVIE. Although reported revenue stayed fairly level from one quarter to the next, that figure conceals substantial strides in foundational efforts that will underpin growth during the second half of the year. Allow me to take you through the drivers in greater depth, starting with ZYNRELEF. Adoption of ZYNRELEF keeps speeding up, with gains in average daily units and total ordering accounts, which now exceed 700 through the month of June. Demand units for ZYNRELEF rose 6.3% versus Q1, indicating ongoing momentum in provider adoption; even so, Q2 revenue took a hit from a temporary inventory drawdown at our wholesalers. This was mainly tied to the shift to the 400-milligram VAN. Such wholesaler inventory swings are typical during new product transitions, and we estimate the effect was a reduction in net sales of roughly $400,000 during the quarter. Crucially, this drawdown took place even as end-user demand kept climbing, and we anticipate wholesaler ordering patterns will return to normal in Q3. On the operational side, we concentrated the ZYNRELEF team on targeted pull-through in accounts where formulary access is already secured. This alignment keeps our reps focused on turning approved access into genuine utilization; on top of that, we introduced several improvements aimed at driving long-term growth. We rolled out a substantially strengthened per unit compensation program with CrossLink. Starting in July, CrossLink reps could nominate as many as 4 accounts per territory with little or no historical ZYNRELEF use, where they think they can deliver an immediate impact. A large number of these accounts already had formulary access, and the enhanced incentives remain in place through the end of 2025; furthermore, we established a new Post-Operative Clinical Educator Team. These 3 specialists deliver targeted onboarding and support in high-volume accounts, boosting adoption efficiency while freeing reps to concentrate on growth. And notably, we obtained a permanent J-code for ZYNRELEF effective October 1. Though it isn't a near-term growth catalyst by itself, the J-code simplifies reimbursement and ought to enhance billing clarity. Considered together, these initiatives amount to a reoriented and focused ZYNRELEF commercial engine, well positioned for acceleration during the second half of the year. Moving to APONVIE; we keep witnessing strong trends approaching the 1,000 average daily unit mark through the month of June, while ex-factory units climbed 11%, demand units increased 19%. Net revenue rose 9% versus Q1. The gap between demand and revenue mirrors inventory normalization at the wholesaler level and a modest effect from standard 340B discounts as larger hospital systems came online during the quarter. To keep our growth going, a specialized APONVIE sales force was brought on board as of July 1, made up of 6 representatives who get support from the national account group. No additional headcount expense was needed to form this group, because we strategically merged territories that weren't performing well. Our expectation is that this focused spending will drive more hospital accounts to convert moving forward. Results from the oncology franchise keep surpassing what we anticipated, with net revenues combined across CINVANTI and SUSTOL hitting $26.5 million in the quarter and $55.1 million for the year so far. In a fiercely competitive landscape, we've held onto our market share, and we're confident these products will keep producing steady results through 2025. We're very happy with how the oncology supportive care franchise has performed, and we're actively looking at inventive approaches to fuel ongoing expansion in this market. To sum up, Q2 centered on restructuring and refocusing our commercial platform. We streamlined the sales force and set up dedicated teams for ZYNRELEF and APONVIE; we partnered with CrossLink to improve pull-through in targeted accounts. High-volume institutions received support from dedicated Clinical Educators, and we achieved genuine gains in demand despite short-term revenue challenges; now that these adjustments are in place, we think Heron is positioned well to achieve accelerating growth across the latter half of 2025 and afterward. Thank you. And now I'll hand things back over to you, Craig.
Thanks, Mark. Turning now to how we did financially. For the 3 months that concluded on June 30, 2025, product gross profit came in at $27.3 million, or 73.5%. That's up from 70.8% during the equivalent stretch of 2024. Across the 6 months that concluded on June 30, 2025, product gross profit reached $57.8 million, or 75.9%, an improvement over 73.2% in the equivalent stretch of 2024. The driver was more units sold, carrying a higher cost per unit than during 2024 because of the supplier mix, partly offset by reduced inventory reserves and write-offs. SG&A expenses for the 3 and 6 months that concluded on June 30, 2025, came to $26 million and $51.1 million, respectively, versus $27.5 million and $53.9 million, respectively, in the equivalent stretches of 2024. Looking at the 3 months that concluded on June 30, 2025, the drop in SG&A expense stems mostly from a $1.8 million reduction in personnel and related expenses, driven by terminations along with onetime stock expense during 2024. Looking at the 6 months that concluded on June 30, 2025, the drop in SG&A expense stems mostly from a $3.5 million reduction in personnel and related expenses, driven by the terminations along with onetime stock expense during 2024. Offsetting these drops was a $600,000 rise in marketing costs, tied mainly to ZYNRELEF. Research and development expenses came to $2.9 million and $5.2 million, respectively, across the 3 and 6 months that concluded on June 30, 2025, versus $4.4 million and $9 million, respectively, in the comparable stretches of 2024. The drop in research and development expense across the 3 months that concluded on June 30, 2025, stems mostly from $1.2 million more of property and equipment write-offs during 2024 than during 2025, plus a $300,000 reduction in personnel and related expenses, driven by terminations. The drop in research and development expense across the 6 months that concluded on June 30, 2025, stems mostly from the $1.2 million more of property and equipment write-off during 2024 than during 2025, plus a $2 million reduction in personnel and related expenses, driven by terminations. Across the 3 months that concluded on June 30, 2025, we posted a net loss of $2.4 million, versus a net loss of $9.2 million in the equivalent stretch of 2024. Across the 6 months that concluded on June 30, 2025, we generated net income of $300,000, versus a net loss of $12.4 million in the equivalent stretch of 2024. Cash and short-term investments stood at $40.6 million on June 30, 2025. Had we excluded depreciation and stock-based compensation, our adjusted EBITDA results would have shown positive operating income of $1.8 million across the 3 months that concluded on June 30, 2025, versus a loss of $1.2 million across the 3 months that concluded on June 30, 2024. Across the 6 months that concluded on June 30, 2025, our adjusted EBITDA is $7.9 million of operating income, versus a loss of $1.9 million in the equivalent stretch of 2024. On August 8, 2025, we completed a refinancing made up of 4 transactions happening at the same time. First, there's a new credit facility with Hercules Capital providing up to $150 million in aggregate principal, which includes $110 million funded when we closed, plus another $40 million accessible through future tranches if milestones are met. Second, we issued and sold $35 million of new 5% senior convertible notes maturing in 2031 to Rubric Capital. Third, there's a placement of common stock and Series A Preferred Stock with certain investors, generating aggregate gross proceeds of roughly $28 million. And finally, an exchange transaction with the holder of our current convertible notes, which involves paying back in cash the majority of our outstanding 1.5% senior convertible notes due in May of 2026, along with converting a portion of what remains of those notes into shares of common stock. The $150 million of aggregate principal amount outstanding on our existing 1.5% senior convertible notes due 2026, as well as the $25.7 million of aggregate principal amount outstanding under our prior Hercules Working Capital Facility, will be completely repaid and extinguished when these transactions close, which should happen on August 12, 2025. Now turning to 2025 financial guidance. Given how our business continues to perform, we're keeping our net revenue guidance the same as before at $153 million to $163 million, and we're changing our earlier adjusted EBITDA guidance of $4 million to $12 million to a range of $9 million to $13 million. At this point we'd like to open the call for any questions.
So I have a question about ZYNRELEF. Could you share more specifics regarding the VAN 400-milligram switch, and what portion of Q2 revenue got affected? And perhaps how much of that effect came from timing, and do you anticipate it will completely return to normal during the second half, with the VAN transition wrapping up in the third quarter? And I have one more question after that.
Thanks for asking. The VAN 400-milligram transition started at the close of Q4, so basically late December. Throughout most of Q1, we were transitioning. And come Q2, we had stopped selling any of the VVS, but the inventory buildup that happened at the end of Q4 and carried into Q1 didn't return to normal until Q2. So we do anticipate that the Q3 inventory normalization will be finished as of July 1.
Understood. Regarding the J-code for ZYNRELEF, could you perhaps share a few remarks about what part it plays in reimbursement, together with the NOPAIN act, and what you expect for adoption going forward?
Clara, it's Craig here. Well, listen, securing the J-code made us happy. From what we've observed as time has gone by while we went through reimbursement using the C-code — it isn't that the C-code goes unrecognized — but the J-code enjoys far broader acceptance, so to speak; and with commercial payers in particular, they are far more accustomed to working with it; so my sense is that with NOPAIN, what will emerge as time goes on, and we're already starting to witness this among some payers, is that they will follow whatever CMS or Medicare does. Should that become more common, we believe once more that possessing a J-code will simply make reimbursement smoother and easier; so we don't really expect any immediate effect. Yet as things develop and commercial payers get on board and reimbursement becomes increasingly equivalent to, put simply, these products getting paid for separately from the surgical bundle, I believe a change will come about in which this J-code genuinely benefits us over the longer term.
Congratulations on everything you've accomplished.
I've only got a couple of things. I'm sorry if some of this was already addressed — I've been jumping between calls. First, regarding the reorganization of the ZYNRELEF sales force, could you explain what prompted it and how it affects the CrossLink partnership? Second, for APONVIE, demand appears to have risen 19% while revenue rose 9%. Is that simply inventory fluctuation? Or are you shifting your pricing strategy as a way to build volume for that product?
Brandon, I appreciate the question. Regarding the ZYNRELEF sales force, before July 1, we had a single team that was basically split 50 to 50 between APONVIE and ZYNRELEF. However, after assessing the team, we concluded that the profiles of these 2 teams ought to differ when it comes to skill set, since a ZYNRELEF rep is mainly concentrated in the OR with surgeons, while an APONVIE rep is generally your conventional hospital sales rep. Because of that, we separated the teams. The ZYNRELEF team remained fairly close to how it was before. The APONVIE team is small — just 6 IBMs, or Institutional Business Managers, at present — yet we believe the group we've installed there will make a significant difference for APONVIE over the long run. When it comes to CrossLink, we have a very good agreement with them. That began in 2024. We've established a strong nationwide network, but our goal was to get them engaged and concentrated on particular accounts. So we've let them select 4 accounts from a list we supply, mainly accounts where formulary access already exists. We've substantially increased the incentive tied to those accounts on a per-unit basis, and we've matched that with the targets of our existing ZYNRELEF sales team too. As a result, we believe we're far better targeted regarding overlap between the 2 teams, and the incentives are now in place to genuinely build momentum in the back half of the year. As for APONVIE sales, it's mostly wholesaler inventory adjustments from us reducing inventory after Q4 and Q1. There's a little gross-to-net effect in there, since 2 or 3 large academic centers came online during the quarter, and there was some sort of skew in how much 340B they were acquiring — but we do expect that to even out over the second half as more accounts continue to be added.
So I suppose my next question concerns the adjustments to the sales force. Does this amount to simply narrowing the focus onto those 2 particular products? Or does the restructuring bring with it some growth in headcount? Then second, on the subject of ZYNRELEF, my understanding is that NOPAIN for Heron took effect in April. I'm therefore wondering whether you have seen any shift in how ZYNRELEF is used or taken up across that move away from your initial pass-through reimbursement toward NOPAIN. Perhaps one final item for Ira: what is the fresh total share count following this morning's transactions?
I'll handle the restructuring question, then Craig can address NOPAIN, and after that we'll hand things to Ira for the share count. Regarding the restructuring, over the near term we don't anticipate the teams growing larger than they are as of today. What you're seeing amounts to a tighter, more focused effort from a single dedicated ZYNRELEF team, whereas previously those same people were also doing their utmost to find sufficient time to sell APONVIE. As for what those reps look like, we regard them as somewhat distinct when it comes to the strategy itself. That's why we separated them. For APONVIE we brought on traditional hospital reps; so that by itself represents a modest bit of growth, yet we managed to accomplish the whole thing without meaningfully increasing costs in the near term.
Right, Serge, let me build on what you said. If you look at the nation as a whole and consider our work with ZYNRELEF along with how it intersects with CrossLink, picture it as clusters — pods, or maybe postage stamps — scattered across the map. Now that we've tidied up the balance sheet and brought in some additional capital, our view — and we're already catching glimpses of this, since CrossLink is far more involved thanks to certain incentives we've put in place — is that certain zones will start gaining serious momentum. So when it comes to growing our footprint and matters of that sort, should those zones emerge, clearly we'll direct additional resources their way. That's precisely where future expansion might happen. That said, this remains a watch-and-wait situation. Rather than indiscriminately scattering funds and deploying 100 reps and so forth, our preference is to proceed methodically and with greater efficiency. Over the past 2 years at minimum, I believe we've demonstrated a highly steady approach to steering the company's finances and everything related. We intend to keep that up moving forward. Now, regarding your question on NOPAIN and how it unfolds — no instant effect has appeared as of yet. What we do notice is that pharmacy-level discussions differ somewhat from how they used to go. To clarify what I mean: typically a rep comes through the door, it's a branded item, and you're stuck grabbing the final spot in the lot, so to speak. But my sense is things have opened up more, since everybody's discussing reimbursement and recognizing these items may represent profit rather than expense. Consequently, as I mentioned earlier regarding commercial payers joining in, I believe a genuine transformation will occur across the coming year or so — commercial payers getting involved, everyone methodically embracing this approach to reimbursement, and viewing it somewhat differently than they might have previously. So once more, factor in VAN, the CrossLink incentive, plus what we're executing from a structural perspective, and we simply sense abundant tailwinds propelling us the right way. And Ira, I'll hand the final portion over to you.
Right, so on a pro forma basis, common shares come to roughly 183 million, and if you factor in the convert, pro forma shares would land at around 208 million.
Nice work on the advancements. I was curious whether you might share the interest rate tied to that senior credit facility involving Hercules; and additionally, regarding the amount of cash, once you subtract expenses and so forth, that will land on the balance sheet when everything is finalized, leaving out the extra $40 million in tranches?
Sure. Carl, that total rate comes in slightly above 10%, and what reaches the balance sheet, net of every expense, is roughly $11 million to $12 million.
Nope. I appreciate all of you for asking questions today. I realize we didn't give much warning. We're grateful that each of you joined in, and we'll speak with you again in the next quarter.
Appreciate it, everyone, for joining us on this call. That brings the event to a close. Please go ahead and hang up at this time. Have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.